Skip to main
ALNY

Alnylam Pharmaceuticals (ALNY) P/E Ratio

P/E Ratio as of Jan 8, 2026: 1661.40

Average1674.98
Median1663.00
Minimum1627.16
Maximum1788.77
1661.40
244.26 (12.82%)past month
The P/E ratio for Alnylam Pharmaceuticals (ALNY) is 1661.40 as of Jan 8, 2026. This represents a increase of 388.86% compared to its 12-month average P/E ratio of 339.85. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.

Alnylam Pharmaceuticals P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)

Alnylam Pharmaceuticals’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Alnylam Pharmaceuticals to industry peers.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Alnylam Pharmaceuticals (ALNY) P/E Ratio Historic Data

DateStock priceP/E ratio
Dec 1, 2025$454.561890.85
Nov 3, 2025$434.071805.62
Oct 1, 2025$460.65-186.72
Sep 2, 2025$447.00-181.19
Aug 1, 2025$401.80-162.87
Jul 1, 2025$322.06-153.88
Jun 2, 2025$306.09-146.25
May 1, 2025$255.13-117.44
Apr 1, 2025$255.76-117.73
Mar 3, 2025$243.53-112.10
Feb 3, 2025$274.55-104.74
Jan 2, 2025$233.62-89.13

Alnylam Pharmaceuticals (ALNY) End of Year P/E Ratio

DateP/E ratioChange
20261661.40+0.44%
20251654.12-1,942.62%
2024-89.77+94.56%
2023-46.14+89.72%
2022-24.32+3.18%
2021-23.57

FAQs About Alnylam Pharmaceuticals (ALNY) P/E ratio

The latest P/E ratio of Alnylam Pharmaceuticals (ALNY) is 1661.40, as of Jan 8, 2026. This is calculated based on its current stock price and earnings per share (EPS).

Alnylam Pharmaceuticals’s last 12-month average P/E ratio is 339.85, compared to its current P/E ratio of 1661.40. This reflects a increase of 388.86%.

Alnylam Pharmaceuticals’s current P/E ratio of 1661.40 is higher than its last 12-month average P/E of 339.85. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.

Alnylam Pharmaceuticals’s average P/E ratio over the last 3 years is 39.95. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.

Alnylam Pharmaceuticals’s average P/E ratio over the last 5 years is 15.33. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.

Alnylam Pharmaceuticals (ALNY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.